Physician profile
Perry Herson
NPI 1396811725
$363,672.79
in general payments reported to CMS, 2019-2025
49 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $35K · 2021: $37K · 2022: $82K · 2023: $91K · 2024: $22K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $107K · Food and Beverage: $18K · Honoraria: $9,100 · Travel and Lodging: $3,051 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,750 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,381.25 |
| Food and Beverage | $17,774.79 |
| Honoraria | $9,100.00 |
| Travel and Lodging | $3,050.53 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,750.00 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuity Medical INC | $61,204.13 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56,401.51 | 2019-2025 | Jardiance, Tradjenta, Glyxambi |
| Astrazeneca Pharmaceuticals Lp | $54,766.48 | 2019-2023 | Farxiga |
| Mannkind Corporation | $54,129.67 | 2019-2025 | Afrezza, V-Go |
| Lilly USA, LLC | $46,668.19 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $30,239.59 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28,938.56 | 2019-2023 | Cycloset |
| Xeris Pharmaceuticals, INC. | $10,728.39 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Merck Sharp & Dohme LLC | $7,648.84 | 2019-2023 | Steglatro |
| Abbott Laboratories | $2,114.00 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $1,665.57 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Insulet Corporation | $1,435.00 | 2019-2023 | Omnipod |
| Amgen INC. | $1,156.52 | 2019-2025 | Tepezza, Evenity, Prolia |
| Dexcom, INC. | $809.00 | 2020-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $789.18 | 2019-2025 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $685.56 | 2021-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $604.92 | 2021-2025 | Unithroid |
| Ibsa Pharma INC. | $525.33 | 2019-2025 | Tirosint, Licart, Tirosint |
| Ascendis Pharma Endocrinology INC | $519.16 | 2023-2025 | Yorvipath |
| Madrigal Pharmaceuticals | $210.70 | 2025 | Rezdiffra |
| Vivus LLC | $207.38 | 2021-2025 | Qsymia |
| Amryt Pharma Holdings Ltd | $181.39 | 2022-2023 | Mycapssa |
| Ascensia Diabetes Care US INC. | $172.11 | 2023 | |
| Esperion Therapeutics, INC. | $167.51 | 2024 | Nexletol, Nexlizet |
| Becton, Dickinson and Company | $161.37 | 2019-2022 | |
| Grt US Holding, INC. | $151.19 | 2022 | |
| Recordati_rare_diseases_inc. | $144.02 | 2023-2025 | Isturisa, Signifor Lar |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $121.88 | 2019-2022 | |
| Intra-Sana Laboratories | $103.83 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Medtronic, INC. | $101.04 | 2021-2023 | Minimed 780g |
| Acerus Pharmaceuticals Corporation | $96.25 | 2020-2022 | |
| Horizon Therapeutics Plc | $83.20 | 2019-2023 | Tepezza |
| Pfizer INC. | $69.24 | 2023-2024 | |
| Lifescan, INC. | $68.98 | 2019-2021 | |
| Zealand Pharma US, INC. | $66.18 | 2021-2022 | |
| Aytu Biopharma, INC. | $59.64 | 2020 | |
| Embecta Corp. | $54.57 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Antares Pharma, INC. | $40.46 | 2022-2024 | Xyosted |
| Medtronic Minimed, INC. | $38.32 | 2019-2020 | |
| Radius Health, INC. | $37.47 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $34.69 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $32.81 | 2019-2020 | |
| Tolmar, INC. | $26.42 | 2024 | |
| Shire North American Group INC | $24.71 | 2019 | |
| Bigfoot Biomedical INC | $19.18 | 2022 | |
| Cequr Corporation | $17.15 | 2023 | Cequr Simplicity |
| Vistapharm, INC. | $14.11 | 2021 | |
| Genzyme Corporation | $12.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Herson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.